Benjamin Ware
Internal Medicine · Aston, PANPI 1073048575
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 346 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 9.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,581, more than ten times the $24 reported in 2020. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 346 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$615
- Pfizer$594
- AstraZeneca$582
- Novo Nordisk$496
- AbbVie$396
- Harmony Biosciences LLC$372
- plus $4K from 32 others
What the payments were for
- Food & beverage$6,576100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 27 | $615 |
| Pfizer | 38 | $594 |
| AstraZeneca | 30 | $582 |
| Novo Nordisk | 27 | $496 |
| AbbVie | 22 | $396 |
| Harmony Biosciences LLC | 12 | $372 |
| Exact Sciences | 15 | $293 |
| Lilly USA, LLC | 15 | $285 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $261 |
| Amgen | 21 | $237 |
| Otsuka America Pharmaceutical, Inc. | 12 | $229 |
| Boehringer Ingelheim | 9 | $213 |
| Sanofi-aventis U.S. LLC | 7 | $157 |
| Astellas Pharma US Inc | 10 | $148 |
| Teva Pharmaceuticals USA, Inc. | 9 | $147 |
| Axsome Therapeutics, Inc. | 6 | $145 |
| Braeburn Inc. | 7 | $141 |
| Phathom Pharmaceuticals, Inc. | 9 | $132 |
| Kowa Pharmaceuticals America, Inc. | 7 | $112 |
| Bayer | 4 | $96 |
| Esperion Therapeutics, Inc. | 5 | $91 |
| Indivior Inc. | 5 | $89 |
| Collegium Pharmaceutical, Inc. | 4 | $81 |
| Sumitomo Pharma America, Inc. | 4 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| Idorsia Pharmaceuticals US Inc | 3 | $65 |
| Seqirus USA Inc | 3 | $63 |
| Dexcom, Inc. | 2 | $56 |
| Alkermes, Inc. | 2 | $56 |
| Shield Therapeutics Inc | 1 | $44 |
| Eisai Inc. | 2 | $44 |
| Paratek Pharmaceuticals, Inc. | 2 | $43 |
| Ardelyx, Inc. | 2 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Lundbeck LLC | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Almatica Pharma LLC | 1 | $20 |
| Novartis | 1 | $16 |
How this compares
$6,576 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 45 | $42,346 |
| OzempicSemaglutide | 24 | $33,527 |
| MounjaroTirzepatide | 16 | $22,067 |
| JardianceEmpagliflozin | 11 | $18,060 |
| FarxigaDapagliflozin Propanediol | 12 | $14,700 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $11,720 |
| MyrbetriqMirabegron | 12 | $7,044 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 49 | $4,711 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $2,995 |
| Atorvastatin Calcium | 195 | $2,713 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 19 | $1,568 |
| Memantine Hcl | 21 | $1,458 |
| Tamsulosin Hcl | 76 | $1,443 |
| Fluticasone Propionate | 149 | $1,365 |
| Valsartan | 34 | $1,324 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $594 | $42,34645 claims |
| Novo NordiskOzempic | $496 | $33,52724 claims |
| Lilly USA, LLCMounjaro | $285 | $22,06716 claims |
| Boehringer IngelheimJardiance | $213 | $18,06011 claims |
| AstraZenecaFarxiga | $582 | $14,70012 claims |
| GSKTrelegy Ellipta | $615 | $11,72011 claims |
| Astellas Pharma US IncMyrbetriq | $148 | $7,04412 claims |
| Almatica Pharma LLCSertraline Hcl | $20 | $44658 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Aston
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- Mohammed KidwaiBala Cynwyd$894K
- Ronak BhimaniNorristown$623K
- David GoldmannPhiladelphia$525K
- Christopher StillDanville$442K
- Jeffrey FreidLower Gwynedd$425K
- Cheryl PegusSpring House$370K
- Eyob FeyssaPhiladelphia$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.